Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.
Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Spironolactone for the Treatment of Melasma
- Conditions
- Melasma
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Medical University of South Carolina
- Registration Number
- NCT03953209
- Locations
- 🇺🇸
Medical University of SC, Charleston, South Carolina, United States
Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation
- Conditions
- AFib
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Piedmont Healthcare
- Target Recruit Count
- 50
- Registration Number
- NCT03929718
- Locations
- 🇺🇸
Piedmont Heart Institute, Atlanta, Georgia, United States
Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)
- Conditions
- Drug Drug Interaction
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- CMP Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT03909529
- Locations
- 🇮🇳
ClinSync Clinical Research Pvt. Ltd., Hyderabad,, Telangana, India
Venetoclax and Lintuzumab-Ac225 in AML Patients
- Conditions
- Acute Myeloid LeukemiaRelapsed Adult AML
- Interventions
- First Posted Date
- 2019-03-08
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Actinium Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT03867682
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸University of Louisville, Louisville, Kentucky, United States
Spironolactone Versus Prednisolone in DMD
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Kevin Flanigan
- Target Recruit Count
- 2
- Registration Number
- NCT03777319
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Dr Irmela MANTEL
- Target Recruit Count
- 20
- Registration Number
- NCT03744767
Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 68
- Registration Number
- NCT03682497
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Spironolactone Versus Indapamide in Obese and Hypertensive Patients
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT03626506
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT03597035
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Blockade of the Renin-angiotensin-aldosterone System in Patients with ARVD
- Conditions
- Arrhythmogenic Right Ventricular Dysplasia
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 120
- Registration Number
- NCT03593317
- Locations
- 🇫🇷
CHU Amiens Picardie, Amiens, France
🇫🇷Hôpital Cardiologique Louis Pradel, Bron, France
🇫🇷Hôpital Gabriel Montpied, Clermont-ferrand, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.